Recently, based on data from a global, randomized phase 2-3 study, RELATIVITY-047 (11), the FDA approved relatlimab, the first immunotherapy that targets the lymphocyte activation gene-3 (LAG-3) for patients aged 12 and older with untreated metastatic or unresectable melanoma, combined with the PD-1 inhibitor nivolumab. This evidence concerns the gene PDCD1 and melanoma.